Sotera Health Company (SHC)

Ligand Pharmaceuticals Stock Forecast

Stock Price Forecast

The 5 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $16, which forecasts a 16.41% increase in the stock price over the next year. The lowest target is $13 and the highest is $20.

Price Target: $16 (+16.41%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$13	$16	$17	$20
Change	-5.42%	+16.41%	+23.68%	+45.51%

* Price targets were last updated on Jun 24, 2025.

Analyst Ratings

The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Mar '25	Apr '25	May '25	Jun '25	Jul '25	Aug '25
Strong Buy	2	1	2	2	2	2
Buy	2	2	2	2	2	2
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	4	5	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Luke Sergott Barclays	Barclays	Buy Maintains $15 → $13	Buy	Maintains	$15 → $13	-5.42%	Jun 24, 2025
Matthew Sykes Goldman Sachs	Goldman Sachs	Hold → Strong Buy Upgrades $14 → $17	Hold → Strong Buy	Upgrades	$14 → $17	+23.68%	May 5, 2025
Jason Bednar Piper Sandler	Piper Sandler	Hold Maintains $15 → $13	Hold	Maintains	$15 → $13	-5.42%	Apr 23, 2025
Luke Sergott Barclays	Barclays	Buy Maintains $16 → $12	Buy	Maintains	$16 → $12	-12.70%	Apr 10, 2025
Luke Sergott Barclays	Barclays	Buy Maintains $17 → $16	Buy	Maintains	$17 → $16	+16.41%	Feb 28, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.15B

Increased by 4.87%

from 1.10B

Revenue Next Year

1.22B

Increased by 5.89%

from 1.15B

EPS This Year

0.76

Increased by 381.83%

from 0.16

EPS Next Year

0.86

Increased by 13.79%

from 0.76

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	818.16M	931.48M	1.00B	1.05B	1.10B	1.15B	1.22B	1.30B
Revenue Growth	5.12%	13.85%	7.75%	4.54%	4.88%	4.87%	5.89%	6.30%
EPS	-0.16	0.41	-0.83	0.18	0.16	0.76	0.86	0.96
EPS Growth	-	-	-	-	-12.89%	381.83%	13.79%	11.22%
Forward PE	-	-	-	-	-	18.19	15.99	14.38
No. Analysts	-	-	-	-	-	8	8	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028
High	1.2B	1.3B	1.4B
Avg	1.2B	1.2B	1.3B
Low	1.1B	1.2B	1.2B

Revenue Growth

Revenue Growth	2025	2026	2027	2028
High	9.9%	11.4%	11.7%
Avg	4.9%	5.9%	6.3%
Low	0.9%	1.7%	1.6%

EPS Forecast

EPS	2025	2026	2027	2028
High	0.82	0.93	1.04
Avg	0.76	0.86	0.96
Low	0.72	0.80	0.91

EPS Growth

EPS Growth	2025	2026	2027	2028
High	422.3%	23.3%	20.9%
Avg	381.8%	13.8%	11.2%
Low	361.9%	6.4%	6.0%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.